According to a media release issued by a Canadian company called Profound Medical on August 16, the US Food and Drug Administration (FDA) has approved the use of a system called TULSA-PRO for the “ablation of prostate tissue”. There appears to be no relevant information on the FDA web site — as yet. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ablation, energy, Profound, thermal, transurethral, TULSA-PRO, ultrasound | Leave a comment »
There is no standard definition of SECOND biochemical (PSA-detected) recurrence (BCR); that is, recurrence after both prostatectomy and salvage radiation (SRT). … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: BCR, biochemical, definition, fourth, recurrence, second, third | 1 Comment »
In 2011, the American Society for Radiation Oncology (ASTRO) issued a consensus statement as part of its “Choosing Wisely” campaign that found that 30 Gy in 10 fractions (treatments), 20 Gy in 5 fractions, and 8 Gy in 1 fraction all gave equivalent pain relief. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: bone, pain, radiotherapy, relief | 7 Comments »
Patients who are initially diagnosed with primary Gleason pattern 5 localized prostate cancer (i.e., having Gleason scores of 5 + 5 = 10 and 5 + 4 = 9) are well understood to have very high-risk disease. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: 5, Gleason, medicine, pattern, precision, risk | 3 Comments »
The initial data from the ARCHES study of standard ADT + enzalutamide versus standard ADT + a placebo in men with metastatic, hormone-sensitive prostate cancer were reported earlier this year at the Genitourinary Cancers Symposium in San Francisco. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, ADT, androgen, apalutamide, darolutamide, deprivation, enzalutamide | 7 Comments »
